OLIVIA KEMNITZ: Open Payments
NPI 1356103691 · HIXSON, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$288 in 16 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $31 · 2025 $288
Food & beverage: $288
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Novo Nordisk Inc | 2 | $36 |
| Dexcom, Inc. | 2 | $30 |
| Lilly USA, LLC | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Amgen Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ABBVIE INC. | 1 | $15 |
Products named: FANAPT, CAPLYTA, Wegovy, Dexcom G6 Transmitter, MOUNJARO, TRELEGY ELLIPTA, KRYSTEXXA, REXULTI.
Industry payments across TN — which companies pay providers there.
